8-K: DBV Technologies Announces Positive 3-Year Results for Viaskin Peanut Patch in Toddlers

DBV Technologies reports positive three-year results from its EPITOPE open-label extension study, demonstrating continued improvement in treatment benefit of the Viaskin Peanut patch in toddlers.

Summary

• DBV Technologies announced positive 3-year results from the EPITOPE open-label extension study for its Viaskin Peanut patch.
• The study showed continued improvement in treatment benefit for toddlers aged 1-3 years over 36 months.
• 68.2% of subjects completed an oral food challenge without meeting stopping criteria at month 36, compared to 30.7% at month 12.
• 83.5% of participants reached an eliciting dose (ED) of 1000 mg at month 36, up from 64.2% at month 12.
• 72.7% of participants reached an ED of 2000 mg at month 36, compared to 37.0% at month 12.
• There were no treatment-related anaphylaxis or serious treatment-related adverse events in year three.
• The company also presented data on daily patch wear time, showing that consistent wear time of 20 hours or more per day correlated with better efficacy.
• Subjects with low day-to-day variability in daily wear time had higher average daily wear time and a more robust efficacy response at 12 months.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with strong efficacy and safety data, suggesting a high likelihood of regulatory approval and commercial success. The management commentary is also very positive.

Positives

• The Viaskin Peanut patch demonstrated continued improvement in efficacy over three years of treatment.
• A significant increase in the percentage of subjects completing the oral food challenge without meeting stopping criteria was observed.
• The study showed a substantial increase in the percentage of participants reaching higher eliciting doses.
• The safety profile of the patch remained strong, with no treatment-related anaphylaxis or serious adverse events in year three.
• Data on patch wear time provides valuable insights for optimizing treatment outcomes.
• The results support the company's proposed labeling approach with the FDA.

Negatives

• Some participants experienced local application-site reactions, although these occurred less frequently in year three.
• A subset of participants had lower average daily wear time, which correlated with a less robust efficacy response.

Risks

• The product is still under development and has not been authorized for sale in any country.
• There are uncertainties associated with research and development, clinical trials, and regulatory reviews.
• The company's ability to execute on its budget discipline measures could impact the product's development.
• There is a risk that the product may not receive regulatory approval or may not be commercially successful.

Future Outlook

DBV Technologies is preparing to initiate the COMFORT Toddlers supplemental safety study, which is one of the final steps to support a BLA submission to the FDA. The company believes that Viaskin Peanut has the potential to revolutionize the treatment of peanut allergy.

Management Comments

• The compelling results from 36 months of Viaskin Peanut treatment demonstrate a continuation of the very positive efficacy and safety trends that have been previously observed in this study, said Pharis Mohideen, Chief Medical Officer, DBV Technologies.
• The data show that more than two-thirds of subjects completed the food challenge without meeting pre-defined stopping criteria, consuming the equivalent of 12-14 peanut kernels, and more than 83% reached an ED of 1,000mg, or the equivalent of 3-4 peanut kernels.
• Average daily wear time is something that can easily be reported by my caregivers and patients and can be a very useful tool for me to guide shared decision making, stated Dr. Edwin Kim, Division Chief, Pediatric Allergy & Immunology, University of North Carolina School of Medicine, and presenting author.
• We are very pleased with the progress that DBV continues to make advancing this novel therapy through its remaining regulatory steps, and believe that, if approved, it has the potential to revolutionize the treatment of peanut allergy, stated Eleanor Garrow-Holding, CEO, Food Allergy and Anaphylaxis Connection Team.

Industry Context

This announcement is significant in the context of the food allergy treatment landscape, as it provides further evidence of the potential of epicutaneous immunotherapy using the Viaskin patch. The positive results could position DBV Technologies as a leader in the development of non-invasive treatments for food allergies.

Comparison to Industry Standards

• The results of the EPITOPE study are promising when compared to other peanut allergy treatments, particularly in the context of long-term efficacy and safety.
• While other companies are exploring oral immunotherapy, DBV's epicutaneous approach offers a non-invasive alternative, which may be more appealing to some patients and caregivers.
• The high percentage of subjects reaching higher eliciting doses and completing food challenges without meeting stopping criteria suggests a strong treatment effect compared to historical data from other studies.
• The focus on average daily wear time and its correlation with efficacy is a unique aspect of DBV's approach, which could lead to more personalized treatment strategies.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients and caregivers of children with peanut allergies may have increased hope for a new treatment option.
• Employees of DBV Technologies may be motivated by the positive progress of the company's lead product.
• The results could also impact the competitive landscape for food allergy treatments.

Next Steps

• DBV Technologies will initiate the COMFORT Toddlers supplemental safety study.
• The company plans to submit a BLA to the FDA.
• DBV will continue to present data at scientific conferences.

Key Dates

Keywords

Viaskin Peanut, Peanut Allergy, Epicutaneous Immunotherapy, EPITOPE, Food Allergy, DBV Technologies, Clinical Trial, Toddlers, Efficacy, Safety